Literature DB >> 23110985

Graft-versus-host disease: state of the science.

Amin M Alousi1, Javier Bolaños-Meade, Stephanie J Lee.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23110985      PMCID： PMC4116672          DOI： 10.1016/j.bbmt.2012.10.028

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  34 in total

1.  Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.

Authors:  Howard M Shulman; David Kleiner; Stephanie J Lee; Thomas Morton; Steven Z Pavletic; Evan Farmer; J Margaret Moresi; Joel Greenson; Anne Janin; Paul J Martin; George McDonald; Mary E D Flowers; Maria Turner; Jane Atkinson; Jay Lefkowitch; M Kay Washington; Victor G Prieto; Stella K Kim; Zsolt Argenyi; A Hafeez Diwan; Asif Rashid; Kim Hiatt; Dan Couriel; Kirk Schultz; Sharon Hymes; Georgia B Vogelsang
Journal:  Biol Blood Marrow Transplant       Date:  2006-01       Impact factor: 5.742

2.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.

Authors:  Steven Z Pavletic; Paul Martin; Stephanie J Lee; Sandra Mitchell; David Jacobsohn; Edward W Cowen; Maria L Turner; Gorgun Akpek; Andrew Gilman; George McDonald; Mark Schubert; Ann Berger; Peter Bross; Jason W Chien; Daniel Couriel; J P Dunn; Jane Fall-Dickson; Ann Farrell; Mary E D Flowers; Hildegard Greinix; Steven Hirschfeld; Lynn Gerber; Stella Kim; Robert Knobler; Peter A Lachenbruch; Frederick W Miller; Barbara Mittleman; Esperanza Papadopoulos; Susan K Parsons; Donna Przepiorka; Michael Robinson; Michael Ward; Bryce Reeve; Lisa G Rider; Howard Shulman; Kirk R Schultz; Daniel Weisdorf; Georgia B Vogelsang
Journal:  Biol Blood Marrow Transplant       Date:  2006-03       Impact factor: 5.742

3.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

4.  A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment.

Authors:  P J Martin; G Schoch; L Fisher; V Byers; F R Appelbaum; G B McDonald; R Storb; J A Hansen
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

5.  A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment.

Authors:  P J Martin; G Schoch; L Fisher; V Byers; C Anasetti; F R Appelbaum; P G Beatty; K Doney; G B McDonald; J E Sanders
Journal:  Blood       Date:  1990-10-15       Impact factor: 22.113

6.  A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease.

Authors:  L Cragg; B R Blazar; T Defor; N Kolatker; W Miller; J Kersey; M Ramsay; P McGlave; A Filipovich; D Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

7.  Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.

Authors:  Kirk R Schultz; David B Miklos; Daniel Fowler; Ken Cooke; Judith Shizuru; Emmanuel Zorn; Ernst Holler; James Ferrara; Howard Shulman; Stephanie J Lee; Paul Martin; Alexandra H Filipovich; Mary E D Flowers; Daniel Weisdorf; Daniel Couriel; Peter A Lachenbruch; Barbara Mittleman; Georgia B Vogelsang; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2006-02       Impact factor: 5.742

8.  Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.

Authors:  Stephanie J Lee; David Zahrieh; Edward Agura; Margaret L MacMillan; Richard T Maziarz; Philip L McCarthy; Vincent T Ho; Corey Cutler; Edwin P Alyea; Joseph H Antin; Robert J Soiffer
Journal:  Blood       Date:  2004-05-11       Impact factor: 22.113

9.  Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.

Authors:  Daniel Couriel; Paul A Carpenter; Corey Cutler; Javier Bolaños-Meade; Nathaniel S Treister; Juan Gea-Banacloche; Paul Shaughnessy; Sharon Hymes; Stella Kim; Alan S Wayne; Jason W Chien; Joyce Neumann; Sandra Mitchell; Karen Syrjala; Carina K Moravec; Linda Abramovitz; Jerry Liebermann; Ann Berger; Lynn Gerber; Mary Schubert; Alexandra H Filipovich; Daniel Weisdorf; Mark M Schubert; Howard Shulman; Kirk Schultz; Barbara Mittelman; Steven Pavletic; Georgia B Vogelsang; Paul J Martin; Stephanie J Lee; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2006-04       Impact factor: 5.742

10.  Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.

Authors:  D Weisdorf; R Haake; B Blazar; W Miller; P McGlave; N Ramsay; J Kersey; A Filipovich
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113
View more
  9 in total

1.  Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.

Authors:  Amin M Alousi; Jonathan E Brammer; Rima M Saliba; Borje Andersson; Uday Popat; Chitra Hosing; Roy Jones; Elizabeth J Shpall; Issa Khouri; Muzaffar Qazilbash; Yago Nieto; Nina Shah; Sairah Ahmed; Betul Oran; Gheath Al Atrash; Stefan Ciurea; Partow Kebriaei; Julianne Chen; Gabriela Rondon; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-07       Impact factor: 5.742

2.  Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.

Authors:  Rudolph Kirk R Schultz; Kevin Scott Baker; Jaap J Boelens; Catherine M Bollard; R Maarten Egeler; Mort Cowan; Ruth Ladenstein; Arjan Lankester; Franco Locatelli; Anita Lawitschka; John E Levine; Mignon Loh; Eneida Nemecek; Charlotte Niemeyer; Vinod K Prasad; Vanderson Rocha; Shalini Shenoy; Brigitte Strahm; Paul Veys; Donna Wall; Peter Bader; Stephan A Grupp; Michael A Pulsipher; Christina Peters
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-21       Impact factor: 5.742

3.  A randomized clinical trial of a parent-focused social-cognitive processing intervention for caregivers of children undergoing hematopoetic stem cell transplantation.

Authors:  Sharon Manne; Laura Mee; Abraham Bartell; Stephen Sands; Deborah A Kashy
Journal:  J Consult Clin Psychol       Date:  2016-02-25

4.  Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Gunjan L Shah; Michael Scordo; Satyajit Kosuri; Diego Adrianzen Herrera; Christina Cho; Sean M Devlin; Taylor Borrill; Dean C Carlow; Scott T Avecilla; Richard C Meagher; Richard J O'Reilly; Ann A Jakubowski; Esperanza B Papadopoulos; Guenther Koehne; Boglarka Gyurkocza; Hugo Castro-Malaspina; Brian C Shaffer; Miguel-Angel Perales; Sergio A Giralt; Roni Tamari
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-22       Impact factor: 5.742

5.  Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia.

Authors:  Juliet N Barker; Mingwei Fei; Chatchada Karanes; Mitchell Horwitz; Steven Devine; Tamila L Kindwall-Keller; Jennifer Holter; Alexia Adams; Brent Logan; Willis H Navarro; Marcie Riches
Journal:  Br J Haematol       Date:  2014-10-01       Impact factor: 6.998

Review 6.  New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).

Authors:  Hannah Choe; James L M Ferrara
Journal:  Expert Opin Ther Targets       Date:  2021-11-01       Impact factor: 6.902

7.  Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Erin Gatza; Thomas Braun; John E Levine; James L M Ferrara; Shuang Zhao; Tianyi Wang; Lawrence Chang; Andrew Harris; Attaphol Pawarode; Carrie Kitko; John M Magenau; Gregory A Yanik; Daniel R Couriel; Steven Goldstein; James Connelly; Pavan Reddy; Sophie Paczesny; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

8.  Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation.

Authors:  Roald Lindås; Tor Henrik Andersson Tvedt; Kimberley Joanne Hatfield; Håkon Reikvam; Oystein Bruserud
Journal:  J Transplant       Date:  2014-10-08

9.  Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.

Authors:  Xin He; YongBin Ye; XiaoJun Xu; Jing Wang; YuXian Huang; GuangYang Weng; MingWan Zhang; KunYuan Guo
Journal:  Biomed Res Int       Date:  2016-10-24       Impact factor: 3.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.